An optimal window of platelet reactivity by LTA assay for patients undergoing percutaneous coronary intervention

Thrombosis Journal

Table 2 Baseline characteristics and medications

	IW*	OW†	P
	n = 506	n = 1203	P
Age	65 (58,72)	64 (56,71)	0.104
Gender (%)	74.70	75.40	0.763
BMI (kg/cm²)	24.73 (22.84,26.60)	24.51 (22.76,26.54)	0.702
History of CABG (%)	1.20	0.70	0.376
History of PCI (%)	10.50	8.10	0.122
Cardiovascular risk factor
Smoking (%)	46.20	46.30	0.983
Hypertension (%)	68.00	64.70	0.188
Diabetes (%)	26.50	25.10	0.551
Angiography and intervention
SYNTAX score	15 (9,21.50)	15 (9,21.50)	0.44
Length of stent	39 (24,66)	39 (24,62)	0.856
Number of stent	2 (1,3)	2 (1,3)	0.737
Biology
HB(g/L)	136 (125,146)	136 (125,146)	0.988
PLT (×10⁹)	186 (157,227)	186 (155,222)	0.996
LDL (mmol/L)	2.57 (2.06,3.24)	2.49 (2.04,3.12)	0.382
eGFR (ml/min.1.732)	89.51 (77.34,103.95)	89.59 (76.43,104.85)	0.93
APTT (s)	25.90 (23.50,28.40)	25.70 (23.60,28.20)	0.787
INR	1.02 (0.98,1.07)	1.02 (0.98,1.06)	0.609
Medications
ACEI/ARB (%)	57.70	56.20	0.564
β blocker (%)	66.80	65.10	0.497
Statin (%)	96.40	96.20	0.815
IIb/IIIa inhibitor (%)	2.20	1.20	0.108

Data are presented as median (interquartile range) or percentage as appropriate. * IW: 25.5% ≤ PL_ADP < 37.5%; † OW: PL_ADP < 25.5% or ≥ 37.5%
IW inside the window, OW outside the window, BMI body mass index, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, MACE major adverse clinical events, HB Hemoglobin, PLT platelet count, LDL low density lipoprotein, eGFR estimated glomerular filtration rate, APTT activated partial thromboplastin time, INR international normalized ratio, ACEI/ARB angiotension converting enzyme inhibitors/ angiotension receptor blocker, IIb/IIIa glycoprotein IIb/IIIa inhibitors

ISSN: 1477-9560